Sunday, May 11

Biogen Idec Strengthens Position as a Leader in Neurology with 38 Data Presentations at 62nd Annual Meeting of the American Academy of Neurology

(Posted By: Josi Creek)

CAMBRIDGE, Mass., Apr 05, 2010 (BUSINESS WIRE) ----Biogen Idec (NASDAQ: BIIB) today announced that 38 company-sponsored platform and poster presentations will be presented during the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 -- 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists. These presentations include data on five compounds that are marketed or currently in development by Biogen Idec and its partners for the treatment of multiple sclerosis (MS), including two approved therapies for MS, TYSABRI(R) (natalizumab) and AVONEX(R) (interferon beta-1a), and three promising compounds in the late stages of development: BG-12 (dimethyl fumarate), PEGylated interferon beta-1a and daclizumab.